文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.

作者信息

Sinn P, Aulmann S, Wirtz R, Schott S, Marmé F, Varga Z, Lebeau A, Kreipe H, Schneeweiss A

机构信息

Department of Pathology, University of Heidelberg, Heidelberg.

Stratifyer Molecular Pathology GmbH, Köln.

出版信息

Geburtshilfe Frauenheilkd. 2013 Sep;73(9):932-940. doi: 10.1055/s-0033-1350831.

DOI:10.1055/s-0033-1350831
PMID:24771945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3859151/
Abstract

Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.

摘要

相似文献

[1]
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.

Geburtshilfe Frauenheilkd. 2013-9

[2]
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.

Health Technol Assess. 2019-6

[3]
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Health Technol Assess. 2013-10

[4]
[A Review Multigene Assays for Clinical Utility in Breast Cancer].

Gan To Kagaku Ryoho. 2016-11

[5]
Genomic Signatures in Luminal Breast Cancer.

Breast Care (Basel). 2020-8

[6]
Clinical utility of multigene profiling assays in early-stage breast cancer.

Curr Oncol. 2017-10

[7]
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.

Front Med (Lausanne). 2018-9-4

[8]
Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow.

Cancer Treat Rev. 2013-9-29

[9]
MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.

Radiology. 2016-11

[10]
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Breast. 2009-10

引用本文的文献

[1]
Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.

Oncogene. 2025-5

[2]
FEN1 Inhibition as a Potential Novel Targeted Therapy against Breast Cancer and the Prognostic Relevance of FEN1.

Int J Mol Sci. 2024-2-9

[3]
Determinants of response to CDK4/6 inhibitors in the real-world setting.

NPJ Precis Oncol. 2023-9-13

[4]
The Enigma of Mammaglobin: Redefining the Biomarker Paradigm in Breast Carcinoma.

Int J Mol Sci. 2023-8-29

[5]
Neurooncology: 2023 update.

Free Neuropathol. 2023-3-20

[6]
Genomic assays for lobular breast carcinoma.

J Clin Transl Res. 2022-11-10

[7]
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.

Int J Mol Sci. 2022-8-5

[8]
Classification and Treatment of Diseases in the Age of Genome Medicine Based on Pathway Pathology.

Int J Mol Sci. 2021-8-30

[9]
Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer.

Front Oncol. 2021-4-26

[10]
Genomic Assays in Node Positive Breast Cancer Patients: A Review.

Front Oncol. 2021-2-16

本文引用的文献

[1]
The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions.

PLoS One. 2013-6-27

[2]
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

J Clin Oncol. 2013-7-1

[3]
Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour.

Breast. 2013-6-24

[4]
Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss.

Mod Pathol. 2013-4-5

[5]
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.

PLoS One. 2013-3-7

[6]
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.

Breast Cancer Res Treat. 2013-2-20

[7]
Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.

Expert Rev Anticancer Ther. 2013-2

[8]
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Ann Oncol. 2013-1-20

[9]
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.

Ann Oncol. 2012-11-7

[10]
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

Ann Oncol. 2012-11-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索